Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging

Medical Hypotheses

Volumn 77, Issue 5, 2011, Pages 884-888

  Obeid, Rima ^a   Shannan, Batool ^a,b   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b IUST   (Syrian Arab Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COBALAMIN; INSULIN; MEGALIN; METFORMIN; TRANSCOBALAMIN;

AGING; ALBUMINURIA; ARTICLE; CELL AGING; CELL LEVEL; CHEMICAL REACTION; COBALAMIN DEFICIENCY; DIABETES MELLITUS; GLYCATION; HOMEOSTASIS; HUMAN; KIDNEY DISEASE; MILLARD REACTION; POLYMORPHONUCLEAR CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY;

AGED; AGING; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY TUBULES, PROXIMAL; MAILLARD REACTION; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 80054008985     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.08.002     Document Type: Article

References (62)

1. Wolff S.P., Jiang Z.Y., Hunt J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991, 10:339-352.
2. Fujimoto N., Yajima M., Ohnishi Y., Tajima S., Ishibashi A., Hata Y., et al. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis. J Invest Dermatol 2002, 118:479-484.
3. Ko S.Y., Lin Y.P., Lin Y.S., Chang S.S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 2010, 49:474-480.
4. Mott J.D., Khalifah R.G., Nagase H., Shield C.F., Hudson J.K., Hudson B.G. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997, 52:1302-1312.
5. Tessier F.J. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris) 2010, 58:214-219.
6. Holmquist W.R., Schroeder W.A. A new N-terminal blocking group involving a Schiff base in hemoglobin AIc. Biochemistry 1966, 5:2489-2503.
7. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta 1968, 22:296-298.
8. Tanzer M.L. Cross-linking of collagen. Science 1973, 180:561-566.
9. Mester L., Kraska B., Crisba J., Mester M. Proceedings: sugar-amine interactions in the blood clotting system and their effects on haemostasis. Thromb Diath Haemorrh 1975, 34:573-574.
10. Ahmed N., Mirshekar-Syahkal B., Kennish L., Karachalias N., Babaei-Jadidi R., Thornalley P.J. Assay of advanced glycation end products in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 2005, 49:691-699.
11. Semba R.D., Fink J.C., Sun K., Windham B.G., Ferrucci L. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. J Ren Nutr 2010, 20:74-81.
12. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fujii W., Yanagisawa K., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997, 46:895-899.
13. Forbes J.M., Thallas V., Thomas M.C., Founds H.W., Burns W.C., Jerums G., et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003, 17:1762-1764.
14. Soulis T., Thallas V., Youssef S., Gilbert R.E., McWilliam B.G., Murray-McIntosh R.P., et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997, 40:619-628.
15. Vidal-Alaball J., Butler C.C. Reduced serum vitamin B-12 in patients taking metformin. BMJ 2010, 340:c2198.
16. Cerami A., Stevens V.J., Monnier V.M. Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus. Metabolism 1979, 28:431-437.
17. Mukhopadhyay S., Kar M., Das K.P. Effect of methylglyoxal modification of human alpha-crystallin on the structure, stability and chaperone function. Protein J 2010, 29:551-556.
18. Miyazawa T, Nakagawa K, Shimasaki S, Nagai R. Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids 2010, in press.
19. Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?. Atherosclerosis 1993, 102:63-67.
20. Brown R.H. Amyotrophic lateral sclerosis. Insights from genetics. Arch Neurol 1997, 54:1246-1250.
21. Chou S.M., Wang H.S., Taniguchi A., Bucala R. Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med 1998, 4:324-332.
22. Ouslimani N., Mahrouf M., Peynet J., Bonnefont-Rousselot D., Cosson C., Legrand A., et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007, 56:308-313.
23. Schurman L., McCarthy A.D., Sedlinsky C., Gangoiti M.V., Arnol V., Bruzzone L., et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008, 116:333-340.
24. Andersen C.B., Madsen M., Storm T., Moestrup S.K., Andersen G.R. Structural basis for receptor recognition of vitamin-B(12)-intrinsic factor complexes. Nature 2010, 464:445-448.
25. Gräsbeck R. Imerslund-Grasbeck syndrome (selective vitamin B(12) malabsorption with proteinuria). Orphanet J Rare Dis 2006, 1:17.
26. Beedholm-Ebsen R., van de W.K., Hardlei T., Nexo E., Borst P., Moestrup S.K. Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood 2010, 115:1632-1639.
27. Seetharam B., Bose S., Li N. Cellular import of cobalamin (vitamin B-12). J Nutr 1999, 129:1761-1764.
28. Wuerges J., Geremia S., Randaccio L. Structural study on ligand specificity of human vitamin B12 transporters. Biochem J 2007, 403:431-440.
29. Regec A., Quadros E.V., Platica O., Rothenberg S.P. The cloning and characterization of the human transcobalamin II gene. Blood 1995, 85:2711-2719.
30. Pathare P.M., Wilbur D.S., Heusser S., Quadros E.V., McLoughlin P., Morgan A.C. Synthesis of cobalamin-biotin conjugates that vary in the position of cobalamin coupling. Evaluation of cobalamin derivative binding to transcobalamin II. Bioconjug Chem 1996, 7:217-232.
31. McGreevy J.M., Cannon M.J., Grissom C.B. Minimally invasive lymphatic mapping using fluorescently labeled vitamin B12. J Surg Res 2003, 111:38-44.
32. Amagasaki T., Green R., Jacobsen D.W. Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells. Blood 1990, 76:1380-1386.
33. Rachmilewitz B., Sulkes A., Rachmilewitz M., Fuks Z. Serum transcobalamin II levels in breast carcinoma patients. Isr J Med Sci 1981, 17:874-878.
34. Bauer J.A., Morrison B.H., Grane R.W., Jacobs B.S., Dabney S., Gamero A.M., et al. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Natl Cancer Inst 2002, 94:1010-1019.
35. Fiskerstrand T., Riedel B., Ueland P.M., Seetharam B., Pezacka E.H., Gulati S., et al. Disruption of a regulatory system involving cobalamin distribution and function in a methionine-dependent human glioma cell line. J Biol Chem 1998, 273:20180-20184.
36. Lai S.C., Nakayama Y., Sequeira J.M., Quadros E.V. Down-regulation of transcobalamin receptor TCblR/CD320 by siRNA inhibits cobalamin uptake and proliferation of cells in culture. Exp Cell Res 2011, 317:1603-1607.
37. Bose S., Seetharam S., Seetharam B. Membrane expression and interactions of human transcobalamin II receptor. J Biol Chem 1995, 270:8152-8157.
38. England J.D., Gronseth G.S., Franklin G., Carter G.T., Kinsella L.J., Cohen J.A., et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009, 72:177-184.
39. Solomon L.R. Diabetes as a cause of clinically significant functional cobalamin deficiency. Diabetes Care 2011, 34:1077-1080.
40. Gorson K.C., Ropper A.H. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006, 77:354-358.
41. Obeid R., Kuhlmann M.K., Kohler H., Herrmann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 2005, 51:196-201.
42. Herrmann W., Obeid R., Schorr H., Geisel J. The usefulness of holotranscobalamin in predicting vitamin B12 status in different clinical settings. Curr Drug Metab 2005, 6:47-53.
43. Carmel R., Vasireddy H., Aurangzeb I., George K. High serum cobalamin levels in the clinical setting-clinical associations and holo-transcobalamin changes. Clin Lab Haematol 2001, 23:365-371.
44. Looker H.C., Fagot-Campagna A., Gunter E.W., Pfeiffer C.M., Sievers M.L., Bennett P.H., et al. Homocysteine and vitamin B(12) concentrations and mortality rates in type 2 diabetes. Diabetes Metab Res Rev 2007, 23:193-201.
45. Obeid R., Kuhlmann M., Kirsch C.M., Herrmann W. Cellular uptake of vitamin B12 in patients with chronic renal failure. Nephron Clin Pract 2005, 99:c42-c48.
46. Thrailkill K.M., Nimmo T., Bunn R.C., Cockrell G.E., Moreau C.S., Mackintosh S., et al. Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin. Diabetes Care 2009, 32:1266-1268.
47. Wulffele M.G., Kooy A., Lehert P., Bets D., Ogterop J.C., Borger van der B.B., et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003, 254:455-463.
48. Seal E.C., Metz J., Flicker L., Melny J. A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations. J Am Geriatr Soc 2002, 50:146-151.
49. Rajan S., Wallace J.I., Brodkin K.I., Beresford S.A., Allen R.H., Stabler S.P. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002, 50:1789-1795.
50. Eussen S.J., de Groot L.C., Clarke R., Schneede J., Ueland P.M., Hoefnagels W.H., et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med 2005, 165:1167-1172.
51. Moestrup S.K., Birn H., Fischer P.B., Petersen C.M., Verroust P.J., Sim R.B., et al. Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis. Proc Natl Acad Sci USA 1996, 93:8612-8617.
52. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
53. Christensen E.I., Moskaug J.O., Vorum H., Jacobsen C., Gundersen T.E., Nykjaer A., et al. Evidence for an essential role of megalin in transepithelial transport of retinol. J Am Soc Nephrol 1999, 10:685-695.
54. Hilpert J., Nykjaer A., Jacobsen C., Wallukat G., Nielsen R., Moestrup S.K., et al. Megalin antagonizes activation of the parathyroid hormone receptor. J Biol Chem 1999, 274:5620-5625.
55. Cui S., Verroust P.J., Moestrup S.K., Christensen E.I. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996, 271:F900-F907.
56. Orlando R.A., Rader K., Authier F., Yamazaki H., Posner B.I., Bergeron J.J., et al. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 1998, 9:1759-1766.
57. Nielsen R., Courtoy P.J., Jacobsen C., Dom G., Lima W.R., Jadot M., et al. Endocytosis provides a major alternative pathway for lysosomal biogenesis in kidney proximal tubular cells. Proc Natl Acad Sci USA 2007, 104:5407-5412.
58. Saito A., Takeda T., Sato K., Hama H., Tanuma A., Kaseda R., et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann N Y Acad Sci 2005, 1043:637-643.
59. Saito A., Nagai R., Tanuma A., Hama H., Cho K., Takeda T., et al. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. J Am Soc Nephrol 2003, 14:1123-1131.
60. Hryciw D.H., Lee E.M., Pollock C.A., Poronnik P. Molecular changes in proximal tubule function in diabetes mellitus. Clin Exp Pharmacol Physiol 2004, 31:372-379.
61. Aminoff M., Carter J.E., Chadwick R.B., Johnson C., Grasbeck R., Abdelaal M.A., et al. Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. Nat Genet 1999, 21:309-313.
62. Busch M., Franke S., Ruster C., Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010, 40:742-755.